Cannabis Law Report

JANUARY 4, 2022

AUSTIN, Texas–(BUSINESS WIRE)–Anebulo Pharmaceuticals, Inc. Our lead product, ANEB-001, has the potential to rapidly reverse the effects of acute cannabinoid intoxication, a relatively unknown yet serious affliction that sends more than 5,000 Americans to the hospital emergency department every day.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Cannabinoids 52

Cannabis Law Report

SEPTEMBER 22, 2021

Oxford Cannabinoid Technologies Holdings plc. . Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. As Canopy Growth remains focused on commercialisation, this agreement will grant OCT access to the Canopy Library to advance this research.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. Zambon is a multinational pharmaceutical company that focuses on innovation and development with the aim to improve patients’ lives. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Veriheal

JUNE 22, 2021

” The doorways opening to new cannabinoid research are monumental. Over the next decade, the United States could stand to see an explosion in the research of cannabinoid therapies. Go figure the federal government chose Mississippi to be the only state where researchers can access medical cannabis legally.

DEA 65

DEA Access Therapy Cannabinoids 65

Cannabis Law Report

JULY 28, 2021

On 1 June 2021, the Group announced an agreement with Voisin Consulting SARL (“VC”), a life sciences consultancy comprising over 200 professionals in the UK, US and India, with expertise in medical devices, cannabinoids, neurological disorders and addictions.

Cannabinoids 105

Cannabinoids Clinical Trials Safety Medicine 105

Cannabis Law Report

JUNE 1, 2022

This acquisition will accelerate Khiron’s growth in Europe by controlling the complete value chain for its products and gaining direct access to German pharmacies. Pharmadrug GmbH has been active worldwide for almost 40 years as a manufacturer and wholesaler of medicinal products and active pharmaceutical ingredients.

Pharmaceutical 52

Pharmaceutical Medicine Extraction Cannabinoids 52

Cannabis Law Report

OCTOBER 27, 2021

a vertically integrated provider of safe and sustainable specialty ingredients, today announced that it has successfully completed commercial-scale, fermentation-based production campaigns for its Lygos CBx cannabinoid products, including CBG (cannabigerol), CBC (cannabichromene), CBD (cannabidiol), and CBDA (cannabidiolic acid).

Cannabinoids 52

Cannabinoids Pharmaceutical Agriculture CBD 52

Cannabis Law Report

FEBRUARY 7, 2023

Under this new program, Protonify will provide cannabis researchers with complimentary access to its high-purity, pharmaceutical-grade cannabinoid ingredients including THC concentrate and THCA isolate.

Pharmaceutical 52

Pharmaceutical Cannabinoids Concentrates THC 52

Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. What about other medical cannabis products? There are many different medical cannabis products. .

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 1, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it will participate in two investor conferences during the month of December 2021. MyMD Pharmaceuticals, Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain Therapy 52

Veriheal

AUGUST 9, 2023

Recent research reaffirms earlier studies that claim that certain non-marijuana plants contain similar compounds found in cannabis, often called cannabinoids. Even more, CBD is the first FDA-approved pharmaceutical drug for two rare forms of epileptic seizures in kids.

CBD 96

CBD Cannabinoids THC Extraction 96

Cannabis Law Report

JANUARY 13, 2020

12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Work with U.S. Mike Beyer.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

DECEMBER 22, 2021

With growing interest in sustainable and bio-based cannabinoids, and after completing a strategic review of Hyasynth including their intellectual property (IP) and R&D platforms, Organigram remains excited about Hyasynth’s future and growth plans. million of secured convertible debentures in Hyasynth (the “Debentures”).

Cannabinoids 52

Cannabinoids Research and Development Events Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 8, 2021

Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).

Access 97

Access Research and Development Medicine THC 97

Cannabis Law Report

SEPTEMBER 7, 2022

The acquisition by Ramm provides access to HemPoland’s distribution network, recognized premium brands, hemp oil extraction technologies, and an additional synergistic foothold into the European market following the acquisition of Sicily-based Canapar Corp. About RAMM Pharma Corp.

Hemp 59

Hemp Pharmaceutical Extraction Cannabinoids 59

Veriheal

SEPTEMBER 27, 2021

The United Kingdom’s Multiple Sclerosis (MS) Society has taken a stand against restricted access to medical cannabis in the country. Medical cannabis has been legal in the nation for almost three years—so why are MS patients struggling to access the treatment? Yet many people with MS are still unable to access it.”

Treatment 98

Treatment Patients Access Research and Development 98

Veriheal

SEPTEMBER 20, 2021

Now, the latest trend among folks living in states without access to legal cannabis is THC-O. While THC-O could be considered a cannabinoid, it’s better described as a compound due to being synthetically derived from hemp. Cannabinoid therapies and research have started to advance across the United States.

THC 98

THC Cannabinoids Vaping Hemp 98

Veriheal

AUGUST 13, 2020

In talking about cannabis and its uses, a lot of attention is always paid to THC, the most well known cannabinoid in the cannabis plant. CBD is a non-intoxicating cannabinoid that offers many of the same medical benefits as THC. Just a few months ago, Dr. Mechoulam discovered an all-new cannabinoid previously unknown to anyone.

Cannabinoids 98

Cannabinoids Chronic Pain Sleep Pharmaceutical 98

United Patients Group

MAY 17, 2023

Some researchers believe that cannabinoids may help people with ASD manage anxiety and stress by increasing their ability to focus and pay attention. Cannabinoids have been shown to help people with autism manage anxiety and stress.

Sleep 78

Sleep Cannabinoids Patients CBD 78

The Cannigma

JUNE 2, 2022

Ever wondered how cannabinoids like THC or CBD affect your blood? The short answer is – no, in most cases cannabinoids do not seem to act as strong blood thinners. In this study the authors speculated that cannabinoids may be inhibiting an enzyme in blood plasma called thrombin, which promotes blood clotting.

Blood Pressure 112

Blood Pressure Cannabinoids Patients THC 112

Cannabis Law Report

JUNE 17, 2021

NASDAQ: CLVR) said it has entered into an active pharmaceutical ingredient supply agreement with CBD Life Holding SAPI de CV, an emerging leader in the Mexican cannabis industry which offers a line of CBD Wellness and consumer products and medical cannabis products which are under development. Clever Leaves Holdings Inc.

CBD 111

CBD Pharmaceutical Compliance Compliance 111

Cannabis Law Report

FEBRUARY 27, 2022

The research and development company simultaneously retains its listing of shares on the Australian Stock Exchange, but notes that the dual listing means it is more accessible to a wider audience of investors “with sophisticated understandings of medicinal cannabinoids, psychedelic therapies, and pharmaceutical development”.

Medicine 52

Medicine Research and Development Therapy Pharmaceutical 52

Cannabis Law Report

JULY 5, 2021

Bod also has a prescription product available to Australians – a pharmaceutical grade cannabidiol (CBD) based formulation called Medicabilis. Back in May, the company said it was launching a new product based on another cannabinoid – cannabigerol (CBG) – which will be sold under the MediCabilis brand as MediCabilis CBG 50 in the UK.

Cannabinoids 95

Cannabinoids CBD Pharmaceutical Access 95

Cannabis Law Report

FEBRUARY 18, 2022

We are one of the first to successfully complete a commercial shipment of Colombian-manufactured high-CBD pharmaceutical product to Germany available for patients in pharmacies under prescription. In addition, this reflects our increasing know-how to comply with complex and sophisticated regulatory and quality frameworks.

Extraction 52

Extraction Pharmaceutical Patients Cannabinoids 52

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. Whether used alone or in combination with other cannabinoids, CBD has shown promise in addressing a wide range of health concerns.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Cannabis Law Report

APRIL 29, 2022

to expand its capabilities into Europe’s largest medical cannabis market and gain access to around 20,000 pharmacies in Germany through its affiliate Clever Leaves Germany GmbH. Clever Leaves Holdings Inc. BOCA RATON, Fla. and HAMBURG, Germany, April 27, 2022 (GLOBE NEWSWIRE) — Clever Leaves Holdings Inc.

Pharmaceutical 52

Pharmaceutical Compliance Compliance Cannabinoids 52

Cannabis Law Report

OCTOBER 26, 2021

Following this selection, Tilray will supply a variety of its pharmaceutical-grade medical cannabis products, including extracts and dried flower with different degrees of THC and CBD for patients with varying medical conditions.

Pharmaceutical 52

Pharmaceutical Research and Development Patients Access 52

MJ Business Attorneys

JUNE 29, 2018

DEA, the DEA expressed in their brief that they do not wish to control cannabinoids, but rather only those cannabinoids derived from the flowers and resins of a cannabis plant above.3%

DEA 113

DEA CBD Pharmaceutical Research and Development 113

Cannabis Law Report

MARCH 29, 2022

to acquire Dutch medical cannabis company APIRx Pharmaceutical BV. Incannex was one of the first ASX-listed companies to make forays into cannabinoid and psychedelic therapeutic drugs (it was originally a direct-to-consumer dental business, which disrupted the dental space).

Pharmaceutical 52

Pharmaceutical Cannabinoids Data Policy 52

Cannabis Law Report

SEPTEMBER 3, 2021

Flora Lab is acknowledged for its quality procedures which are now in line with global pharmaceutical companies after it receives GMP certification from INVIMA to manufacture cosmetics products. Has the capability to produce cannabinoid-containing products, including cannabidiol (“CBD”). Dietary Supplements. About Flora Growth Corp.

Supply Chain 93

Supply Chain Wellness and Beauty Pharmaceutical Events 93

PrestoDoctor

SEPTEMBER 6, 2023

The plant’s active compounds, cannabinoids, interact with the body’s endocannabinoid system, which plays a crucial role in regulating pain perception. One of the primary reasons for this shift is the growing acceptance and accessibility of cannabis as an alternative pain management option.

Chronic Pain 105

Chronic Pain Research and Development Patients Cannabis 105

Veriheal

DECEMBER 10, 2021

The Louisiana Department of Health recently notified businesses about an opportunity to obtain a license for making foods that contain cannabinoids. Consumable hemp is defined as “any product derived from industrial hemp that contains any cannabinoids and is intended for consumption or topical use.”

THC 98

THC Cannabinoids Hemp Chronic Pain 98

Cannabis Law Report

OCTOBER 12, 2021

Above all, having our own Canadian listing makes it easier for us to gain access to specialized investors. In the Canadian capital market, we also ensure ourselves of a completely different degree of attention to and understanding of our issue – and can thus better exploit the opportunities to access capital.”

Research and Development 52

Research and Development Terpenes Sleep Pharmaceutical 52

Cannabis Law Report

SEPTEMBER 14, 2022

Although a limited number of people have been able to access it via the Peer Approved Clinical System (PACS) Tier 2 individual patient treatment request process. Sativex , which is administered via a mouth spray, contains the cannabinoids CBD and THC.

Treatment 52

Treatment Access Patients Medicine 52

Cannabis Law Report

MARCH 5, 2019

The PDF of the report can be accessed and downloaded at. Cannabis and cannabinoids for medical,scienti?c Pharmaceutical registration and prescription regimes . Medical uses of cannabinoids . ects of short-term medicinal cannabinoid use . Medical use of approved cannabinoids . Here’s the TOC.

Cannabinoids 66

Cannabinoids Pharmaceutical Compliance Compliance 66

The Cannigma

MAY 13, 2022

CBDA is a less studied cannabinoid but it is beginning to gain attention for its potential medical uses for a variety of applications including pain, inflammation, cancer, and COVID-19. While other cannabinoids can also help with some of these issues, CBDA has shown special promise for some of the more debilitating conditions on the list.

Tincture 115

Tincture Cannabinoids Strains CBD 115

Veriheal

OCTOBER 13, 2020

Ethan Russo theorized that IBS may present itself in an individual as a result of a deficiency in the body’s’ own cannabinoid chemicals, which are located in the endocannabinoid system (the ECS). Luckily, Dronabinol can be organically accessed in its botanical form, THC, directly from the plant. . Cannabis for GI Pathologies .

Digestion 123

Digestion Treatment Conditions Research and Development 123